Medscape1d
B-Cell Depleting Drug Shines in IgG4-Related Disease
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
Fate Therapeutics’ FT522 shows efficacy in Phase 2 B-cell lymphoma trial
Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...
Hosted on MSN11d
New CAR T-Cell Therapy Approved for Leukemia
The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...
Cure Today10d
FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based ...
Monthly Prescribing Reference7d
Aucatzyl Approved for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
The Food and Drug Administration (FDA) has approved Aucatzyl ® (obecabtagene autoleucel; obe-cel) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...
The American Journal of Managed Care10d
FDA Approves Obe-Cel for R/R B-Cell Acute Lymphoblastic Leukemia
Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's ...
Targeted Oncology10d
FDA Greenlights Obe-cel in Relapsed/Refractory B-ALL
The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Sean ‘Diddy’ Combs lawyers claim seizure of writings from cell is ‘outrageous government conduct’
Lawyers for Sean ‘Diddy’ Combs say prosecutors have engaged in “outrageous government conduct” by using materials seized from ...
Targeted Oncology4d
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities
Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...